rituximab,cyclophosphamide
biogen,roche
['derm', 'ritux', 'cyclophosphamide', 'imab ']
#acr2022 abstr#0003. subgroup analysis from recital rct rituximab vs cyclophosphamide in ctd-ild showed both therapies improved fvc in myositis and mctd but not scleroderma. to interpret with caution (non-powered). key message: to consider rtx as option for ctd-ild 
Rheumatologist. Interested in B-cells, Lupus, Sjogren, Pre-Connective Tissue Disease, Tennis, Running & Travelling ??